Arrowstreet Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.01M | Sell |
13,664
-2,079
| -13% | -$590K | ﹤0.01% | 1358 |
|
|
2026
Q1 | $4.39M | Buy |
+15,743
| New | +$4.53M | ﹤0.01% | 1200 |
|
|
2025
Q4 | – | Sell |
-13,711
| Closed | -$3.84M | – | 1838 |
|
|
2025
Q3 | $3.84M | Sell |
13,711
-10,266
| -43% | -$2.79M | ﹤0.01% | 1257 |
|
|
2025
Q2 | $5.79M | Buy |
+23,977
| New | +$5.67M | ﹤0.01% | 1112 |
|
|
2025
Q1 | – | Sell |
-36,956
| Closed | -$12.1M | – | 1813 |
|
|
2024
Q4 | $12.1M | Buy |
36,956
+29,707
| +410% | +$10.1M | 0.01% | 768 |
|
|
2024
Q3 | $2.43M | Buy |
+7,249
| New | +$2.3M | ﹤0.01% | 1183 |
|
|
2024
Q2 | – | Sell |
-8,972
| Closed | -$3.1M | – | 1530 |
|
|
2024
Q1 | $3.1M | Buy |
+8,972
| New | +$2.95M | ﹤0.01% | 1027 |
|
|
2023
Q2 | – | Sell |
-11,804
| Closed | -$5.65M | – | 1224 |
|
|
2023
Q1 | $5.65M | Sell |
11,804
-22,745
| -66% | -$10.6M | 0.01% | 670 |
|
|
2022
Q4 | $14.5M | Buy |
34,549
+1,521
| +5% | +$614K | 0.02% | 451 |
|
|
2022
Q3 | $13.8M | Buy |
33,028
+5,487
| +20% | +$2.74M | 0.02% | 452 |
|
|
2022
Q2 | $13.6M | Sell |
27,541
-56,567
| -67% | -$29.5M | 0.02% | 443 |
|
|
2022
Q1 | $47.4M | Buy |
84,108
+1,701
| +2% | +$1.03M | 0.06% | 259 |
|
|
2021
Q4 | $62.3M | Sell |
82,407
-7,704
| -9% | -$5.77M | 0.08% | 254 |
|
|
2021
Q3 | $67.2M | Buy |
90,111
+287
| +0.3% | +$215K | 0.08% | 254 |
|
|
2021
Q2 | $57.9M | Buy |
89,824
+30,572
| +52% | +$18.6M | 0.07% | 305 |
|
|
2021
Q1 | $33.8M | Buy |
59,252
+15,859
| +37% | +$9.39M | 0.05% | 402 |
|
|
2020
Q4 | $25.3M | Buy |
43,393
+22,176
| +105% | +$12.6M | 0.04% | 513 |
|
|
2020
Q3 | $10.9M | Buy |
21,217
+4,724
| +29% | +$2.39M | 0.02% | 794 |
|
|
2020
Q2 | $7.45M | Sell |
16,493
-5,000
| -23% | -$2.21M | 0.01% | 892 |
|
|
2020
Q1 | $7.54M | Buy |
21,493
+15,303
| +247% | +$5.63M | 0.02% | 576 |
|
|
2019
Q4 | $2.29M | Sell |
6,190
-12,807
| -67% | -$4.52M | 0.01% | 1101 |
|
|
2019
Q3 | $6.32M | Sell |
18,997
-34,752
| -65% | -$11.3M | 0.01% | 631 |
|
|
2019
Q2 | $16.8M | Sell |
53,749
-11,657
| -18% | -$3.49M | 0.04% | 381 |
|
|
2019
Q1 | $20M | Buy |
65,406
+43,752
| +202% | +$11.8M | 0.05% | 360 |
|
|
2018
Q4 | $5.03M | Buy |
21,654
+14,854
| +218% | +$3.99M | 0.01% | 580 |
|
|
2018
Q3 | $2.13M | Buy |
+6,800
| New | +$2.11M | ﹤0.01% | 674 |
|
|
2018
Q2 | – | Sell |
-10,000
| Closed | -$2.5M | – | 1082 |
|
|
2018
Q1 | $2.5M | Buy |
10,000
+1,200
| +14% | +$306K | 0.01% | 708 |
|
|
2017
Q4 | $2.1M | Buy |
8,800
+5,400
| +159% | +$1.31M | 0.01% | 809 |
|
|
2017
Q3 | $756K | Sell |
3,400
-9,600
| -74% | -$2.16M | ﹤0.01% | 871 |
|
|
2017
Q2 | $2.94M | Buy |
13,000
+2,200
| +20% | +$479K | 0.01% | 576 |
|
|
2017
Q1 | $2.15M | Buy |
+10,800
| New | +$2.08M | 0.01% | 802 |
|
|
2016
Q4 | – | Sell |
-5,745
| Closed | -$941K | – | 1690 |
|
|
2016
Q3 | $941K | Buy |
+5,745
| New | +$872K | ﹤0.01% | 1088 |
|
|
2016
Q2 | – | Sell |
-49,796
| Closed | -$6.81M | – | 1334 |
|
|
2016
Q1 | $6.81M | Sell |
49,796
-17,729
| -26% | -$2.33M | 0.03% | 476 |
|
|
2015
Q4 | $9.36M | Buy |
67,525
+1,500
| +2% | +$208K | 0.04% | 366 |
|
|
2015
Q3 | $8.87M | Buy |
66,025
+6,615
| +11% | +$952K | 0.04% | 374 |
|
|
2015
Q2 | $8.95M | Buy |
59,410
+5,690
| +11% | +$814K | 0.05% | 291 |
|
|
2015
Q1 | $7.26M | Sell |
53,720
-1,275
| -2% | -$158K | 0.04% | 341 |
|
|
2014
Q4 | $6.63M | Buy |
54,995
+1,925
| +4% | +$222K | 0.04% | 386 |
|
|
2014
Q3 | $6.02M | Buy |
+53,070
| New | +$6.29M | 0.03% | 372 |
|
|
2014
Q2 | – | Sell |
-25,257
| Closed | -$3.24M | – | 982 |
|
|
2014
Q1 | $3.24M | Buy |
+25,257
| New | +$3.24M | 0.02% | 537 |
|
|
2013
Q4 | – | Sell |
-3,840
| Closed | -$451K | – | 1147 |
|
|
2013
Q3 | $451K | Sell |
3,840
-15,231
| -80% | -$1.8M | ﹤0.01% | 805 |
|
|
2013
Q2 | $2.14M | Buy |
+19,071
| New | +$2.24M | 0.02% | 446 |
|
Other funds holding BIO
AI
Arrowstreet Capital's BIO Position: Q2 2026 in Review
Arrowstreet Capital reduced its Bio-Rad Laboratories Class A (BIO) stake by 13% in Q2 2026, selling an estimated $590K and leaving 13,664 shares worth $4.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1358.
Arrowstreet Capital first reported a position in BIO in Q2 2013 and has held it in 42 quarters since. The position peaked at $67.2M in Q3 2021. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.
- Arrowstreet Capital held 13,664 shares of Bio-Rad Laboratories Class A worth $4.01M as of Q2 2026.
- Arrowstreet Capital sold 2,079 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $590K.
- Bio-Rad Laboratories Class A made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1358 holding.
- Arrowstreet Capital first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 42 quarters since.
- Arrowstreet Capital's Bio-Rad Laboratories Class A position peaked at $67.2M in Q3 2021.
- 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.
Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.